Skip to main content

AIM ImmunoTech Inc.

corporate_fare Company Profile

AIM ImmunoTech Inc.

AIM·NYSE·Life Sciences·CIK 0000946644

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida, focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. The company has established a foundation of laboratory, pre-clinical and clinical data on the development of nucleic acids and natural interferon to enhance the human body's natural antiviral defense system and to aid development of therapeutic products for certain cancers and chronic diseases. AIM's products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). The flagship product, Ampligen, is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). The company's research and development of Ampligen has included conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer; evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors; exploring Ampligen's antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof; evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fatigue and/or the Post-COVID condition of fatigue; and evaluating Ampligen as a vaccine adjuvant in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza.

AIM ImmunoTech Inc. (NYSE:AIM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for AIM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Recent SEC coverage for AIM spans 10-Q.

Recent high-impact activity:

  • AIM ImmunoTech 10-Q: Going Concern Warning, $10.0M Nine-Month Loss, 47.4M Warrants Outstanding

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$88K
Net Income
-$13.96M
Diluted EPS
-$8.62
Op. Cash Flow
-$10.96M
Operating Income
-$11.66M
Cash & Equivalents
$2.98M
Total Debt
$4.48M
Debt / Equity
-0.46×
Net Margin
-158.61×
Shares Outstanding
3.07M sh
Source: 10-K · filed 2026-03-27 · accession 0001493152-26-013301

Short Interest & Short Volume

2.46 days to cover

FINRA reported short interest of 1,002,082 shares in AIM as of the October 30, 2026 settlement, a 7.2% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 26.4% of AIM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,002,082 shares as of October 30, 2026
Change vs prior period▼ 7.2%
Days to cover2.46 at avg daily volume of 406,598
Daily short volume (FINRA facilities)26.4% of 790,379 shares on November 20, 2026
5-day average short volume28.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.1135 -0.96% today
52-week range · as of 2026-11-12 $0.1135 – $1.88
Market cap
$4.57M
Volume
1.3M (2.2× avg)
3-mo avg 569.6K
Live data · 2026-11-21 17:59 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AIM - Latest Insights

AIM
Nov 12, 2026, 4:35 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1486
Real-time Price: $0.1135 info
Change: -$0.0351 (-24%) info
Market Cap: $4.575M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets